Hansa Biopharma AB (publ) (HNSBF) Research

Hansa Biopharma AB (publ) is a biopharmaceutical firm, established in 2007 and headquartered in Lund, Sweden. The company specializes in developing immune-modulating treatments, leveraging its unique enzyme technology platform. Their therapeutic focus areas include facilitating organ transplantation, addressing rare autoimmune conditions mediated by immunoglobulin G (IgG), advancing gene therapy, and combating cancer. Their primary investigational product, Imlifidase, an enzyme designed to cleave antibodies, is currently undergoing advanced clinical trials. It is in Phase 3 for patients requiring sensitized kidney transplants and for treating anti-GBM antibody disease. Furthermore, Imlifidase is being evaluated in Phase 2 studies for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Beyond Imlifidase, Hansa Biopharma is advancing other programs, including NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing), which targets autoimmune conditions, transplantation, and cancer, and EnzE (Enzyme based antibody Enhancement), a cancer immunotherapy. A preclinical research partnership with argenx BV is also underway to assess the synergistic potential of combining their respective IgG-modulating technologies.

Open Hansa Biopharma AB (publ) (HNSBF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.